Moderna, Inc. financial data

Symbol
MRNA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
325 Binney Street, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Moderna Therapeutics, Inc. (to 8/24/2016)
Latest financial report
10-K - Q4 2024 - Feb 21, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 405 % +29.4%
Quick Ratio 13.4 % -12.3%
Debt-to-equity 31.7 % -3.74%
Return On Equity -30.1 % -0.7%
Return On Assets -22.8 % -1.65%
Operating Margin 4.82 % -92.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 386M shares
Common Stock, Shares, Outstanding 386M shares +1.05%
Entity Public Float 42.1B USD +4.73%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 384M shares +0.52%
Weighted Average Number of Shares Outstanding, Diluted 384M shares +0.52%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 10.7B USD -53.7%
Revenue from Contract with Customer, Excluding Assessed Tax 3.24B USD -52.7%
Research and Development Expense 4.54B USD -6.23%
General and Administrative Expense 1.17B USD -24.2%
Costs and Expenses 7.18B USD -35.2%
Operating Income (Loss) -3.95B USD +6.94%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -3.61B USD +8.5%
Income Tax Expense (Benefit) -46M USD -106%
Net Income (Loss) Attributable to Parent -3.56B USD +24.5%
Earnings Per Share, Basic -9.28 USD/shares +24.7%
Earnings Per Share, Diluted -9.28 USD/shares +24.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.93B USD -33.7%
Accounts Receivable, after Allowance for Credit Loss, Current 358M USD -59.9%
Inventory, Net 117M USD -42.1%
Other Assets, Current 58M USD -34.1%
Assets, Current 8.1B USD -21.6%
Deferred Income Tax Assets, Net 81M USD 0%
Operating Lease, Right-of-Use Asset 759M USD +6.45%
Goodwill 52M USD 0%
Other Assets, Noncurrent 594M USD -22.5%
Assets 14.1B USD -23.3%
Accounts Payable, Current 405M USD -22.1%
Employee-related Liabilities, Current 312M USD +27.3%
Accrued Liabilities, Current 1.43B USD -20.6%
Contract with Customer, Liability, Current 153M USD -73.1%
Liabilities, Current 2.21B USD -26.8%
Contract with Customer, Liability, Noncurrent 58M USD -30.1%
Deferred Income Tax Liabilities, Net 231M USD -1.7%
Operating Lease, Liability, Noncurrent 671M USD +4.36%
Other Liabilities, Noncurrent 267M USD +4.3%
Liabilities 3.24B USD -29.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -10M USD +91.9%
Retained Earnings (Accumulated Deficit) 10B USD -26.2%
Stockholders' Equity Attributable to Parent 10.9B USD -21.3%
Liabilities and Equity 14.1B USD -23.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -989M USD +19.3%
Net Cash Provided by (Used in) Financing Activities 14M USD
Net Cash Provided by (Used in) Investing Activities 118M USD -94.1%
Common Stock, Shares Authorized 1.6B shares 0%
Common Stock, Shares, Issued 386M shares +1.05%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -857M USD -451%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.93B USD -34.1%
Deferred Tax Assets, Valuation Allowance 3.08B USD +38.7%
Deferred Tax Assets, Gross 3.36B USD +25.5%
Operating Lease, Liability 685M USD +2.55%
Payments to Acquire Property, Plant, and Equipment 196M USD +73.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -3.45B USD +22.8%
Lessee, Operating Lease, Liability, to be Paid 1.13B USD -0.35%
Operating Lease, Liability, Current 14M USD -44%
Lessee, Operating Lease, Liability, to be Paid, Year Two 73M USD -8.75%
Lessee, Operating Lease, Liability, to be Paid, Year One 71M USD -30.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 444M USD -4.52%
Lessee, Operating Lease, Liability, to be Paid, Year Three 78M USD -4.88%
Deferred Tax Assets, Operating Loss Carryforwards 424M USD +371%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 162M shares 0%
Unrecognized Tax Benefits 240M USD +3.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 81M USD -3.57%
Additional Paid in Capital 866M USD +133%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 185M USD -70%
Deferred Tax Assets, Net of Valuation Allowance 277M USD -39%
Share-based Payment Arrangement, Expense 429M USD +40.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%